Apitope

Apitope, a Belgium-based biotech company founded in 2002, is focused on developing drugs for the treatment of allergic diseases. The company positions itself at the forefront of antigen-specific immunotherapy, employing a proprietary discovery platform for creating peptide-based therapies known as "apitopes®." These therapies aim to restore immune tolerance, providing a targeted approach to autoimmune diseases without the drawbacks of global immune suppression.

The company's leading product candidate, ATX-MS-1467, is in clinical development for multiple sclerosis (MS), offering a promising combination of high efficacy and a differentiating safety profile. Additionally, ATX-GD-59 targets Graves' disease, potentially revolutionizing treatment standards for the first time in over 60 years.

Noteworthy in Apitope's evolution is a €12.00M Series B investment received in September 2015 from investors including Vesalius Biocapital, Arthurian Life Sciences, Wyvern Seed Fund, and PMV Pharmaceuticals.